Shield Therapeutics PLC
STX
Company Profile
Business description
Shield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group’s main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.
Contact
Northern Design Centre
Baltic Business Quarter
Gateshead Quays
NewcastleNE8 3DF
GBRT: +44 1915118500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
73
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,175.10 | 49.90 | 0.61% |
| CAC 40 | 7,543.86 | 41.08 | 0.55% |
| DAX 40 | 22,241.33 | 176.82 | 0.80% |
| Dow JONES (US) | 40,093.40 | 486.83 | 1.23% |
| FTSE 100 | 8,427.66 | 20.22 | 0.24% |
| HKSE | 21,980.74 | 70.98 | 0.32% |
| NASDAQ | 17,166.04 | 457.99 | 2.74% |
| Nikkei 225 | 35,705.74 | 666.59 | 1.90% |
| NZX 50 Index | 12,017.84 | 61.37 | 0.51% |
| S&P 500 | 5,484.77 | 0.00 | 0.00% |
| S&P/ASX 200 | 7,968.20 | 47.70 | 0.60% |
| SSE Composite Index | 3,295.06 | 2.23 | -0.07% |